Physician profile
Jane V Mayrin
NPI 1467679738
$627,862.72
in general payments reported to CMS, 2019-2025
60 companies · $45K in 2025
The $45K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213K · 2020: $124K · 2021: $88K · 2022: $85K · 2023: $43K · 2024: $29K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Food and Beverage: $13K · Travel and Lodging: $11K · Honoraria: $500 · Education: $75.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,978.81 |
| Food and Beverage | $12,593.99 |
| Travel and Lodging | $11,071.75 |
| Honoraria | $500.00 |
| Education | $75.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $272,961.75 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $162,583.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $65,064.48 | 2019-2025 | Farxiga, Lynparza, Lokelma |
| Sanofi-Aventis U.S. LLC | $60,039.28 | 2019-2025 | |
| Amarin Pharma, INC. | $35,673.15 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $12,890.52 | 2019-2020 | |
| Medtronic, INC. | $4,693.67 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Intuity Medical INC | $2,351.31 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Amgen INC. | $1,043.67 | 2019-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $953.39 | 2020-2025 | Jardiance |
| Corcept Therapeutics | $857.60 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $818.77 | 2021-2025 | |
| Radius Health, INC. | $795.51 | 2019-2025 | Tymlos |
| Mannkind Corporation | $775.32 | 2019-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $744.59 | 2020-2024 | Gvoke Hypopen, Recorlev |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.72 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $531.87 | 2021-2025 | Unithroid |
| Novartis Pharmaceuticals Corporation | $475.99 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $365.63 | 2024-2025 | Zenpep |
| Becton, Dickinson and Company | $329.27 | 2019-2022 | |
| Dexcom, INC. | $304.13 | 2022-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $276.26 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Nestle Healthcare Nutrition INC. | $211.38 | 2022-2023 | |
| Astellas Pharma US INC | $198.96 | 2024-2025 | Veozah |
| Amphastar Pharmaceuticals, INC. | $196.70 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.45 | 2019-2023 | Cycloset |
| Almatica Pharma LLC | $152.12 | 2025 | Teriparatide, Loreev Xr |
| Beta Bionics, INC. | $125.32 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Recordati_rare_diseases_inc. | $120.52 | 2024-2025 | Isturisa, Signifor Lar |
| Esperion Therapeutics, INC. | $112.53 | 2023-2025 | Nexletol |
| Abbott Laboratories | $104.41 | 2022-2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $101.68 | 2021-2023 | Strensiq |
| Embecta Corp. | $95.71 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Tolmar, INC. | $81.02 | 2023-2025 | Jatenzo |
| Clarus Therapeutics INC. | $79.72 | 2021 | |
| Tandem Diabetes Care, INC. | $78.14 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $64.09 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $62.25 | 2023-2024 | Crysvita |
| Halozyme INC | $60.54 | 2023 | |
| Soleno Therapeutics, INC. | $58.86 | 2025 | Vykat Xr |
| Ultragenyx Pharmaceutical INC. | $57.34 | 2020-2022 | |
| Ascendis Pharma Endocrinology INC | $47.06 | 2023-2025 | Yorvipath |
| Chiesi USA, INC. | $45.38 | 2024 | Mycapssa |
| Vifor Pharma, INC. | $44.91 | 2025 | Veltassa |
| Vivus LLC | $41.99 | 2021 | |
| Insulet Corporation | $41.86 | 2023-2024 | Omnipod |
| Horizon Therapeutics Plc | $35.97 | 2023 | Tepezza |
| Averitas Pharma INC. | $33.47 | 2023 | Qutenza |
| Endo Pharmaceuticals INC. | $29.33 | 2021 | |
| Opko Pharmaceuticals, LLC | $29.29 | 2019-2021 | |
| Acerus Pharmaceuticals Corporation | $22.63 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $17.90 | 2022 | |
| Medtronic Minimed, INC. | $16.67 | 2020 | |
| Zealand Pharma US, INC. | $15.78 | 2021 | |
| Grt US Holding, INC. | $15.14 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.11 | 2020 | |
| Companion Medical, INC. | $14.98 | 2020 | |
| Sequel Med Tech, LLC | $14.14 | 2025 | Twiist |
| Sanofi US Services INC. | $13.77 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Mayrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.